Optimus to buy Advaxis stock; Former MedImmune exec joins 3-V board;

 @FierceBiotech: Ramius looks to buy out Cypress. Article | Follow @FierceBiotech

> Optimus has committed to purchase up to $7.5 million in Advaxis stock. Advaxis is developing live, attenuated Listeria monocytogenes vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Release

> Menlo Park's 3-V Biosciences has put James Young, who worked 19 years at Medimmune, on its board of directors. Report

> BIO Ventures for Global Health is expanding to the West Coast with the opening of a new San Francisco headquarters office. The expansion provides BVGH the opportunity to work even more closely with the world class biotech and investor communities on both coasts. Release

> Pantec Biosolutions, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced the closing of a CHF $20 million investment achieved by two financing rounds. The StemCell Holding AG, an Austrian investment company in the life sciences sector, acted as lead investor. No further terms were disclosed. Release

> Sir Paul Nurse boasts a long list of academic accolades, among them a Nobel Prize, but his chummy manner and oodles of scientific star power have earned him the nickname "David Beckham of science." Story

> Archer Biosciences announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. Release

> Fujirebio, the diagnostic drug unit of Miraca Holdings, said Tuesday that it will spend 9.7 billion yen to buy Belgian counterpart Innogenetics NV. Story

> Beike Biotechnology, one of the world's leading biotechnology companies focusing on adult stem cell therapies, opened Romania's first rehabilitation center to use traditional Chinese-style rehabilitation techniques in Campina today. Release

And Finally... Melting DNA into a barcode--A completely new method for producing an image of individual DNA molecules' genetic make-up has been developed by researchers in Sweden and Denmark. The results are published in the latest issue of the journal Proceedings of the National Academy of Sciences of the USA (PNAS). Release

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.